Vincristine, Carboplatin, and Etoposide or Observation Only in Treating Patients Who Have Undergone Surgery for Newly Diagnosed Retinoblastoma
Intraocular Retinoblastoma
ClinicalTrials.gov recordTREATMENT READING
Source sections for this topic, with the original link and date. Patient and professional reading are labelled separately.
Not medical advice · Not a complete treatment or trial directory
Made by Triangle.
Selected text from the National Cancer Institute, with the original link and date. Made by Triangle. This page is not an NCI PDQ summary. Source topics may be broader than an individual diagnosis.
Source: Retinoblastoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: April 3, 2025. Captured 2026-09-09.
Treatment planning by a multidisciplinary team of cancer specialists—including a pediatric oncologist, ophthalmologist, and radiation oncologist—with experience treating ocular tumors of childhood is required to optimize treatment outcomes.[1] Evaluation at specialized centers is highly recommended before the initiation of treatment to improve the likelihood of ocular salvage and vision preservation.
Sources: 1
The goals of therapy include the following:
Eradicate the disease to save the patient's life.
Preserve as much vision as possible.
Decrease risk of late sequelae from treatment, particularly subsequent neoplasms (SNs).
Many treatments considered to be standard of care have not been studied in a randomized fashion.
Treatment of retinoblastoma depends on the intraocular and extraocular disease burden, disease laterality, germline RB1 gene status, and the potential for preserving vision. For patients presenting with intraocular disease, particularly those with bilateral eye involvement, a conservative approach consisting of tumor reduction with intravenous or intra-arterial chemotherapy (ophthalmic artery chemotherapy), coupled with aggressive local therapy, may result in high ocular salvage rates.[2] Radiation therapy, one of the most effective treatments in retinoblastoma, is usually reserved for cases of intraocular or extraocular disease progression.
Sources: 2
A risk-adapted, judicious combination of the following therapeutic options should be considered:
Enucleation.
Sources: Enucleation
Local treatment (cryotherapy, laser therapy, and brachytherapy).
Sources: Local treatment (cryotherapy, laser therapy, and brachytherapy)
Systemic chemotherapy.
Sources: Systemic chemotherapy
Intra-arterial chemotherapy (ophthalmic artery infusion of chemotherapy).
Sources: Intra-arterial chemotherapy (ophthalmic artery infusion of chemotherapy)
Intravitreal chemotherapy.
Sources: Intravitreal chemotherapy
Intracameral chemotherapy.
Sources: Intracameral chemotherapy
Radiation therapy (external-beam radiation therapy [EBRT], brachytherapy).
Sources: Radiation therapy (external-beam radiation therapy [EBRT], brachytherapy)
The treatment options for intraocular, extraocular, and recurrent retinoblastoma are described in Table 13.
Sources: Table 13
| Treatment Group | Treatment Options | |
|---|---|---|
| CNS = central nervous system; EBRT = external-beam radiation therapy. | ||
| Intraocular retinoblastoma: | ||
| Unilateral retinoblastoma | Enucleation for large intraocular tumors, with or without adjuvant chemotherapy | |
| Conservative ocular salvage approaches when the eye and vision can be saved: | ||
| —Chemoreduction with either systemic or intra-arterial chemotherapy with or without intravitreal chemotherapy | ||
| —Local treatments (cryotherapy, thermotherapy, and plaque radiation therapy) | ||
| Bilateral retinoblastoma | Enucleation for large intraocular tumors, followed by pathology-based, risk-adapted chemotherapy when the eye and vision cannot be saved | |
| Conservative ocular salvage approaches when the eye and vision can be saved: | ||
| —Chemoreduction with either systemic or intra-arterial chemotherapy with or without intravitreal chemotherapy | ||
| —Local treatments (cryotherapy, thermotherapy, and plaque radiation therapy) | ||
| —EBRT | ||
| Extraocular retinoblastoma: | ||
| Orbital and locoregional retinoblastoma | Chemotherapy | |
| Radiation therapy | ||
| Enucleation (for extraocular extension) | ||
| CNS disease | Systemic chemotherapy and CNS-directed therapy with radiation therapy | |
| Systemic chemotherapy followed by myeloablative chemotherapy and stem cell rescue with or without radiation therapy | ||
| Synchronous trilateral retinoblastoma | Systemic chemotherapy followed by surgery and myeloablative chemotherapy with stem cell rescue | |
| Systemic chemotherapy followed by surgery and radiation therapy | ||
| Extracranial metastatic retinoblastoma | Systemic chemotherapy followed by myeloablative chemotherapy with stem cell rescue and radiation therapy | |
| Progressive or recurrent intraocular retinoblastoma | Enucleation | |
| Radiation therapy (EBRT or plaque radiation therapy) | ||
| Local treatments (cryotherapy or thermotherapy) | ||
| Salvage chemotherapy (systemic or intra-arterial) | ||
| Intravitreal chemotherapy, especially for refractory or recurrent vitreous seeding | ||
| Progressive or recurrent extraocular retinoblastoma | Systemic chemotherapy and radiation therapy for orbital disease | |
| Systemic chemotherapy followed by myeloablative chemotherapy with stem cell rescue, and radiation therapy for extraorbital disease | ||
Sources: Enucleation for large intraocular tumors, with or without adjuvant chemotherapy · Conservative ocular salvage approaches when the eye and vision can be saved: · Enucleation for large intraocular tumors, followed by pathology-based, risk-adapted chemotherapy when the eye and vision cannot be saved · Conservative ocular salvage approaches when the eye and vision can be saved: · Chemotherapy · Radiation therapy · Enucleation · Systemic chemotherapy and CNS-directed therapy with radiation therapy · Systemic chemotherapy followed by myeloablative chemotherapy and stem cell rescue with or without radiation therapy · Systemic chemotherapy followed by surgery and myeloablative chemotherapy with stem cell rescue · Systemic chemotherapy followed by surgery and radiation therapy · Systemic chemotherapy followed by myeloablative chemotherapy with stem cell rescue and radiation therapy · Enucleation · Radiation therapy (EBRT or plaque radiation therapy) · Local treatments (cryotherapy or thermotherapy) · Salvage chemotherapy (systemic or intra-arterial) · Intravitreal chemotherapy, especially for refractory or recurrent vitreous seeding · Systemic chemotherapy and radiation therapy for orbital disease · Systemic chemotherapy followed by myeloablative chemotherapy with stem cell rescue, and radiation therapy for extraorbital disease
This page is made by Triangle. The reading above is selected source text, not a treatment recommendation, and it is not medical advice.
Source: Retinoblastoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: April 3, 2025. Captured 2026-09-09.
Upfront removal of the eye is indicated for large tumors filling the vitreous for which there is little or no likelihood of restoring vision, in cases of extension to the anterior chamber, or in the presence of neovascular glaucoma. Patients must be monitored closely for orbital recurrence of disease, particularly in the first 2 years after enucleation.[3][Level of evidence C1]
Sources: 3 · Level of evidence C1
Enucleation is also used as a salvage treatment in cases of disease progression or recurrence in patients receiving eye-salvage management. The pathology specimen must be carefully examined to identify patients who are at high risk of extraocular dissemination and who may require adjuvant chemotherapy.[4][Level of evidence C1 and C2]
In a retrospective, multicenter, global cohort of patients (n = 1,411) who underwent primary enucleation, the pathological classification of the primary tumor (pT) category (based on the American Joint Committee on Cancer [AJCC] Cancer Staging Manual, 8th edition) was predictive of orbital tumor recurrence, tumor-related metastasis, and tumor-related death. Not receiving adjuvant therapy was associated with increased tumor-related death in pT3a (P < .001), pT3b (P = .009), pT3c (P = .018), and pT4 (P < .001) eyes.[5]
Sources: 5
Enucleation in patients younger than 3 years does not allow for the proper orbital growth during subsequent development, causing asymmetry of the final orbital size.[6]
Sources: 6
Source: Retinoblastoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: April 3, 2025. Captured 2026-09-09.
For patients undergoing eye-salvage treatments, aggressive local therapy is always required. Local treatment is administered by the ophthalmologist directly to the tumor.
Cryotherapy. Cryotherapy is based on the application of a cryoprobe to the sclera in the immediate vicinity of the retinal tumor. Cryotherapy is used as primary therapy or with chemotherapy for tumors smaller than 4 disc diameters (DD) in the anterior portion of the retina.
Laser therapy. Laser therapy may be used as primary therapy for small tumors or in combination with chemotherapy for larger tumors. Traditional photocoagulation (argon laser), in which the laser was applied around the tumor to target the tumor vasculature, has given way to thermotherapy (diode laser). Thermotherapy is delivered directly to the tumor surface via infrared wavelengths of light.[7,8]
Brachytherapy (plaque radiation therapy). For larger tumors that are not amenable to cryotherapy or laser therapy, brachytherapy can provide an effective means for local control. For more information, see the Radiation Therapy section.
Sources: Radiation Therapy
Source: Retinoblastoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: April 3, 2025. Captured 2026-09-09.
Systemic chemotherapy plays a role in the following situations:
Adjuvant setting for patients with high-risk pathology. Different regimens have been used in the management of patients with high-risk pathology in the enucleated specimen. Most regimens include a three-drug combination of vincristine, etoposide, and carboplatin, either alone or alternating with cyclophosphamide and an anthracycline.[5,9-11]; [4][Level of evidence C1 and C2]
Treatment of patients with extraocular and metastatic disease. Patients with extraocular disease benefit from more intensive therapy. While a standard treatment has not been determined, responses to cisplatin-based regimens, with consolidation using high-dose chemotherapy and autologous hematopoietic stem cell rescue for patients with extraorbital disease, have been reported.[12-15]
Chemoreductive treatment in conjunction with aggressive local treatment for patients undergoing ocular salvage treatments. During the past two decades, the standard of care has been systemic chemotherapy to reduce tumor volume (chemoreduction) to facilitate the use of local treatments and to avoid the long-term effects of radiation therapy.[16] The success rate for eye salvage varies from center to center, but overall good ocular outcomes are consistently obtained for discrete tumors without vitreous seeding. In a large cohort analysis of 994 eyes in 554 patients who were treated with intravenous chemotherapy and had long-term outcome data, investigators found that tumor control was strongly dependent on the International Classification of Retinoblastoma group designation per eye. Frontline intravenous chemotherapy consisting of six cycles of vincristine, etoposide, and carboplatin plus additional intra-arterial chemotherapy and/or plaque radiation therapy led to tumor control for Groups A (96%), B (91%), C (91%), D (71%), and E (32%) by year 2. With the aforementioned treatment, enucleation or external-beam radiation therapy could be avoided, and the tumor-controlling effect lasted up to 20 years.[17][Level of evidence C1]Eye grouping, as defined by the International Classification of Retinoblastoma, is the best predictor of ocular salvage using this approach, with salvage rates ranging from 60% to 100%.[16] Prolonged chemotherapy instead of enucleation, in the context of persistent intraocular disease activity, should be used cautiously because this approach has been associated with an increased risk of metastatic disease.[18]; [19][Level of evidence C2]
Sources: 16 · International Classification of Retinoblastoma · 17 · Level of evidence C1 · 16 · 18 · 19 · Level of evidence C2
Source: Retinoblastoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: April 3, 2025. Captured 2026-09-09.
Direct delivery of chemotherapy into the eye via cannulation of the ophthalmic artery is a feasible and effective method for ocular salvage when performed at high-volume centers that have specialized services of an interventional radiologist skilled in this area and a pediatric anesthesiologist. The Children’s Oncology Group conducted a multi-institutional study (ARET12P1 [NCT02097134]) to evaluate the feasibility of administering intra-arterial therapy to newly diagnosed patients with Group D retinoblastoma. The study failed to meet the feasibility goals, highlighting the importance of referring patients to high-volume institutions that have expertise in the procedure.[20] Responses to chemotherapy using this approach can be further consolidated with local control measures, as described above.
Sources: ARET12P1 [NCT02097134] · 20
Melphalan is the most common and most effective agent used for intra-arterial chemotherapy. It is often combined with topotecan or carboplatin when responses are suboptimal or there is very advanced intraocular disease.[21,22]
Outcome after intra-arterial chemotherapy correlates with the extent of intraocular burden, as follows:
Patients with early intraocular disease (Group B and C eyes) have an excellent outcome, with ocular salvage rates exceeding 85%. These patients may be treated with single-agent therapy.[22]
Sources: 22
Patients with Group D eyes have a worse outcome, with ocular salvage rates below 60%.[22] However, ocular salvage rates higher than 80% have been reported in specialized centers.[21,23] For patients with very advanced intraocular disease, an alternative treatment is the use of systemic chemotherapy followed by consolidation with intra-arterial melphalan.[24]
Ocular salvage rates when intra-arterial chemotherapy administration is used as salvage treatment for patients with recurrent or progressive disease are consistently lower, with globe survival rates of 50% to 75%.[21-23] Best results are reported using a more intensive three-drug regimen with melphalan, topotecan, and carboplatin.[25]
The role of intra-arterial chemotherapy in ocular salvage has been further clarified in a multicenter randomized clinical trial. This trial compared intra-arterial chemotherapy with systemic chemotherapy for children with unilateral advanced (Group D or E) retinoblastoma. Patients were randomly assigned to receive either four cycles of intra-arterial melphalan combination chemotherapy (two cycles with carboplatin and two cycles with topotecan) or six cycles of systemic chemotherapy with vincristine, carboplatin, and etoposide. Local control was performed based on standard practice. The 2-year progression-free ocular salvage rates were 53% for patients in the intra-arterial chemotherapy group and 27% for patients in the intravenous chemotherapy group. The ocular salvage rates were 71% for patients who received intra-arterial chemotherapy and 51% for patients who received intravenous chemotherapy.[26]
Sources: 26
Patients with bilateral disease can undergo tandem intra-arterial chemotherapy administration.[27] In those circumstances, patients are at higher risk of systemic toxicity caused by melphalan exposure,[28] and single-agent carboplatin may be used to treat the less-advanced eye during the tandem procedure.[29] For neonates and very young infants in whom the cannulization of the ophthalmic artery is not feasible, bridge treatment with single-agent systemic carboplatin until the infant is aged 3 months or weighs 6 kg, followed by consolidation with intra-arterial chemotherapy, has been shown to be very effective. In one study, the 1-year radiation-free ocular survival rate was 95%.[30]
In a study of 39 infants younger than 3 months with advanced intraocular retinoblastoma (Group D and E eyes), patients received intra-arterial chemotherapy as primary treatment (29 eyes) or secondary treatment (13 eyes previously treated with intravenous chemotherapy) using a microcatheterization procedure. The middle meningeal artery was used when the ophthalmic artery could not be catheterized.[31]
Sources: 31
The globe salvage rate was 96% for the 23 Group D eyes and 33% for the 6 Group E eyes, but the 2-year overall ocular survival rate was 81% because of an increased incidence of phthisis bulbi.
The incidence of complete vision loss was high.
Follow-up was limited, ranging from 6 months to 6 years; therefore, later effects are unknown.
The addition of intravitreal chemotherapy to intra-arterial chemotherapy appears to markedly improve the overall effectiveness in eyes with vitreous seeds, especially those with vitreous seed clouds.[21,32,33] For more information, see the Intravitreal Chemotherapy section.
Sources: 21 · 32 · 33 · Intravitreal Chemotherapy
In patients presenting with total retinal detachment, ophthalmic artery chemosurgery has been shown to promote retinal reattachment.[34]
Sources: 34
Complications related to intra-arterial chemotherapy include the following:[22,26,35]
Retinal detachment (up to 19.3%).[36]
Sources: 36
Vitreous hemorrhage (up to 18.1%).
Ptosis (13.6%).
Dysmotility (6.5%).
Vascular and ischemic effects, including ophthalmic artery stenosis (18%) and occlusion (up to 9%).
Optic atrophy (3.4%).
Phthisis (2.7%).
Major vascular complications related to the procedure are very rare. Strokes or significant acute neurological events have not been reported by the most experienced groups.[21,22,37] However, stenosis of the ophthalmic artery and occlusion of the retinal artery have been documented.[35,37] The risk of thrombosis is significantly increased in children with thrombophilia.[38] In a large series of 196 patients who were treated with 682 infusions of intra-arterial chemotherapy, ophthalmic vascular events were reported in 17% of the treated eyes.[35]
The impact of the intraocular vascular changes on vision has not been fully assessed because of the young age of the first cohorts of patients treated. Most patients do not have substantial electroretinographic changes,[39] and preservation of central vision has been reported.[40] A proportion of patients with abnormal electroretinograms (ERGs) with or without retinal detachment may have improved ERGs in the years after intra-arterial chemotherapy.[41] However, in patients with heavily pretreated eyes, intensive intra-arterial chemotherapy may result in worsening of retinal function.[25]
Another risk associated with intra-arterial chemotherapy is the exposure to ionizing radiation during fluoroscopy. Mean total radiation doses of 42.3 mGy have been reported in very experienced centers.[42] After multiple procedures, cumulative doses can reach 0.1 to 0.2 Gy, which can be cataractogenic and potentially carcinogenic in this susceptible population.[43] There has been no increase in the incidence of second malignancies.[44,45] However, longer follow-up is required to fully ascertain the risks associated with the procedure.
Source: Retinoblastoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: April 3, 2025. Captured 2026-09-09.
Studies suggest that direct intravitreal injection of melphalan or topotecan may be effective in controlling active vitreous seeds.[46,47]; [48,49][Level of evidence C2] A retrospective study of 264 eyes (250 children) treated with intravitreal melphalan for vitreous seeds over a two-decade period reported a complete remission rate of 68%. There was a low incidence of extraocular spread as a result of the injection that occurred in children with high-risk features.[50][Level of evidence C2]
Sources: 46 · 47 · 48 · 49 · Level of evidence C2 · 50 · Level of evidence C2
Because of initial concerns about the potential for tumor dissemination, the use of intravitreal chemotherapy was limited. However, additional reports have estimated that the proportion of patients with extraocular tumor spread, as the result of intravitreal injection, is negligible.[51,52] While this procedure is safe and well tolerated, recent studies have shown a direct correlation between the number of injections and a decrease in retinal function, as measured by ERG.[52]; [53][Level of evidence C3]
Sources: 51 · 52 · 52 · 53 · Level of evidence C3
Preliminary data support that intra-arterial chemotherapy plus intravitreal chemotherapy (as needed for vitreous seeding) may improve globe salvage in eyes with advanced retinoblastoma when compared with children who were treated in earlier years with intra-arterial chemotherapy alone.[52]; [32][Level of evidence C2] Compared with the children treated in the earlier era, children treated in the later era received a combination of intra-arterial and intra-vitreal chemotherapy, which demonstrated shorter time to regression, fewer recurrences, fewer enucleations, and no increased toxicity, including no difference in loss of retinal function as measured by ERG.[33][Level of evidence C3]
Sources: 52 · 32 · Level of evidence C2 · 33 · Level of evidence C3
As experience with the use of intra-vitreal chemotherapy expands, studies have demonstrated its efficacy in controlling subretinal seeds and recurrent retinal tumors, suggesting a potential role beyond the control of vitreous seeds as an adjunctive therapy in the globe-sparing treatment of retinoblastoma.[54]
Sources: 54
Source: Retinoblastoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: April 3, 2025. Captured 2026-09-09.
A retrospective, single-institution study reported on the treatment of anterior chamber seeding with the injection of aqueous melphalan. Ocular salvage was achieved in 6 of 11 eyes (median, four injections), with a mean follow-up of 17 months.[55]
Sources: 55
Source: Retinoblastoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: April 3, 2025. Captured 2026-09-09.
Retinoblastoma is a very radiosensitive malignancy.
EBRT. EBRT doses ranging from 35 Gy to 46 Gy usually result in long-term remissions. Because of the need to sedate young children and the intricacies of field planning, special expertise in pediatric radiation therapy is important. Radiation therapy is used in cases of progression after conservative approaches, in patients with extraocular extension, and as part of the management of patients with metastatic disease.Newer methods of delivering EBRT are being applied to reduce adverse long-term effects. This includes intensity-modulated radiation therapy and proton-beam radiation therapy (charged-particle radiation therapy).[56-59] Preliminary data suggest that proton radiation therapy is associated with a lower risk of radiation-induced malignancy in survivors of heritable retinoblastoma. In a nonrandomized study that compared two contemporary cohorts of patients with heritable retinoblastoma who were treated with either photon or proton radiation therapy, the 10-year cumulative incidence of radiation-induced SNs was significantly different between the two groups (0% for proton radiation vs. 14% for photon radiation, P = .015).[60]EBRT in infants causes growth failure of the orbital bones and results in cosmetic deformity. EBRT also increases the risk of SNs in children with heritable retinoblastoma.
Sources: intensity-modulated radiation therapy · charged-particle radiation therapy · 56 · 59 · 60
Brachytherapy (plaque radiation therapy). Indications for plaque radiation therapy include solitary tumors with a diameter ranging between 6 mm and 15 mm, tumor thickness of 10 mm or less, and tumor location of more than 3 mm from the optic disc or fovea. The most commonly used radioisotope is iodine I 125, although others such as iridium Ir 192 and ruthenium Ru 106 are also effective. In combination with the appropriate use of chemotherapy and other forms of focal consolidation, brachytherapy can be very effective in the treatment of localized retinal tumors that are not amenable to other means of local therapy.[61-63]
Source: Retinoblastoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: April 3, 2025. Captured 2026-09-09.
Cancer in children and adolescents is rare, although the overall incidence has slowly increased since 1975.[1] Children and adolescents with cancer should be referred to medical centers that have a multidisciplinary team of cancer specialists with experience treating the cancers that occur during childhood and adolescence. This multidisciplinary team approach incorporates the skills of the following pediatric specialists and others to ensure that children receive treatment, supportive care, and rehabilitation to achieve optimal survival and quality of life:
Sources: 1
Primary care physicians.
Pediatric surgeons.
Transplant surgeons.
Pathologists.
Pediatric radiation oncologists.
Pediatric medical oncologists and hematologists.
Ophthalmologists.
Rehabilitation specialists.
Pediatric oncology nurses.
Social workers.
Child-life professionals.
Psychologists.
Nutritionists.
For specific information about supportive care for children and adolescents with cancer, see the summaries on Supportive and Palliative Care.
Sources: Supportive and Palliative Care
The American Academy of Pediatrics has outlined guidelines for pediatric cancer centers and their role in the treatment of children and adolescents with cancer.[2] At these centers, clinical trials are available for most types of cancer that occur in children and adolescents, and the opportunity to participate is offered to most patients and their families. Clinical trials for children and adolescents diagnosed with cancer are generally designed to compare potentially better therapy with current standard therapy. Other types of clinical trials test novel therapies when there is no standard therapy for a cancer diagnosis. Most of the progress in identifying curative therapies for childhood cancers has been achieved through clinical trials. Information about ongoing clinical trials is available from the NCI website.
Sources: 2 · NCI website
Dramatic improvements in survival have been achieved for children and adolescents with cancer.[3-5] Between 1975 and 2020, childhood cancer mortality decreased by more than 50%.[3,6,7] Childhood and adolescent cancer survivors require close monitoring because side effects of cancer therapy may persist or develop months or years after treatment. For specific information about the incidence, type, and monitoring of late effects in childhood and adolescent cancer survivors, see Late Effects of Treatment for Childhood Cancer.
Sources: 3 · 5 · 3 · 6 · 7 · Late Effects of Treatment for Childhood Cancer
Source: Retinoblastoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: April 3, 2025. Captured 2026-09-09.
Source: Retinoblastoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: April 3, 2025. Captured 2026-09-09.
Treatment options for unilateral intraocular retinoblastoma include the following:
Enucleation for large intraocular tumors, with or without adjuvant chemotherapy based on pathology risk, when the eye cannot be saved.
Conservative ocular salvage approaches when the eye and vision can be saved:
Sources: Conservative ocular salvage approaches when the eye and vision can be saved
Conservative ocular salvage approaches when the eye and vision can be saved:
Chemoreduction with either systemic or intra-arterial chemotherapy with or without intravitreal chemotherapy.
Local treatments, including cryotherapy, thermotherapy, and plaque radiation therapy.
Source: Retinoblastoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: April 3, 2025. Captured 2026-09-09.
Because unilateral disease is usually massive and there is often no expectation that useful vision can be preserved, up-front surgery (enucleation) is commonly performed. Careful examination of the enucleated specimen by an experienced pathologist is necessary to determine whether high-risk features for metastatic disease are present. These high-risk features include the following:[1-5]; [6][Level of evidence C1 and C2]
Anterior chamber seeding.
Massive choroidal involvement.
Tumor beyond the lamina cribrosa.
Scleral and extrascleral extension.
Pre-enucleation magnetic resonance imaging has low sensitivity and specificity for the detection of high-risk pathology.[7]
Sources: 7
High-risk pathology has been associated with the presence of minimal dissemination in bone marrow and cerebrospinal fluid using quantitative polymerase chain reaction for detection of CRX or GD2 synthase. In a group of 96 children with nonmetastatic retinoblastoma and high-risk pathology, the 3-year disease-free survival rate was 78% for patients with detectable minimal dissemination, compared with 98% for those without detectable disease (P = .004).[8]
Sources: 8
Systemic adjuvant therapy with vincristine, doxorubicin, and cyclophosphamide or with vincristine, carboplatin, and etoposide has been used to prevent the development of metastatic disease in patients with certain high-risk features assessed by pathological review after enucleation.[3]
Sources: 3
The Children’s Oncology Group ARET0332 (NCT00335738) trial prospectively studied the role of adjuvant chemotherapy in 321 eligible children with newly diagnosed enucleated unilateral retinoblastoma. Central histopathological review was performed for all patients' pathology slides. Defined indications for adjuvant chemotherapy included massive choroid replacement defined as posterior uveal invasion grades IIC and IID, any posterior uveal involvement less than 3 mm with concomitant optic nerve involvement, and optic nerve involvement posterior to the lamina cribrosa. Treatment consisted of six cycles of carboplatin, etoposide, and vincristine administered every 4 weeks.[6][Level of evidence C1 and C2]
Sources: ARET0332 (NCT00335738) · 6 · C1 · C2
Central review of enucleated eyes by ophthalmic pathologists identified a group of children (19% of all eligible patients) who were misclassified by the institutional pathology report.
The importance of universal guidelines for handling and interpreting retinoblastoma specimens is instrumental in the recognition and categorization of high-risk features.
For all patients on the study, the overall 2-year event-free survival (EFS) rate was 98%, and the overall survival (OS) rate was 99%.
For patients with high-risk features requiring adjuvant chemotherapy, the 2-year EFS rate was 96%.
For patients with low-risk features for whom observation was indicated, the 2-year EFS rate was 99%.
The combination of extensive involvement of both the choroid and the optic nerve posterior to the lamina cribrosa represents the highest risk of recurrence and supports the need for more intensive chemotherapy for this group.
The average time to first recurrence was less than 12 months, and the time to death after recurrence was approximately 8 months.
Source: Retinoblastoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: April 3, 2025. Captured 2026-09-09.
Conservative ocular salvage approaches, such as systemic chemotherapy and local-control treatments, may be offered in an attempt to save the eye and preserve vision.[9] Ocular salvage rates correlate with intraocular grouping. The possibility of saving the eye without the use of external-beam radiation therapy (EBRT) exceeds 80% for children with early intraocular disease. However, the ocular outcomes for children with advanced intraocular disease are poor using systemic chemotherapy and local treatments, with less than 40% ocular salvage rates, even after the use of EBRT.[10] Plaque brachytherapy has been used as a salvage therapy for patients with unilateral retinoblastoma. In one series, 12 eyes in 12 children were treated with ruthenium plaque brachytherapy. Globe salvage was achieved in 75% of the patients. The ultimate local control rate was 66%.[11]
Caution must be used when delaying enucleation by extending treatment with systemic chemotherapy when tumor control does not appear to be possible, particularly for Group E eyes. Pre-enucleation chemotherapy for eyes with advanced intraocular disease may result in downstaging and underestimate the pathological evidence of extraretinal and extraocular disease, thus increasing the risk of dissemination.[12]
Sources: 12
The delivery of chemotherapy via ophthalmic artery cannulation as initial treatment for advanced unilateral retinoblastoma appears to be more effective than systemic chemotherapy for chemoreduction, particularly for Group D eyes.[13,14]; [15][Level of evidence C3] In a multidisciplinary state-of-the-art center, intra-arterial chemotherapy to treat patients with advanced intraocular unilateral retinoblastoma may result in ocular salvage rates of approximately 70% to 90%.[14-18] For more information, see the Intra-Arterial Chemotherapy (Ophthalmic Artery Infusion of Chemotherapy) section.
Sources: 13 · 14 · 15 · Level of evidence C3 · 14 · 18 · Intra-Arterial Chemotherapy (Ophthalmic Artery Infusion of Chemotherapy)
Electroretinography, a technique that measures the electrical responses of various cell types in the retina, including the photoreceptors, can be used to assess retinal function during and after treatment with intra-arterial chemotherapy. In one study, pretreatment electroretinography correlated with final visual acuity after treatment with intra-arterial chemotherapy, suggesting that this technique may potentially be used to help with treatment strategy decisions and prioritization of interventions.[19]
Sources: 19
Source: Retinoblastoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: April 3, 2025. Captured 2026-09-09.
Information about National Cancer Institute (NCI)–supported clinical trials can be found on the NCI website. For information about clinical trials sponsored by other organizations, see the ClinicalTrials.gov website.
Sources: NCI website · ClinicalTrials.gov website
The following is an example of a national and/or institutional clinical trial that is currently being conducted:
ARET2121 (NCT05504291) (A Study to Give Treatment Inside the Eye to Treat Retinoblastoma): This trial is exploring the feasibility of incorporating intravitreal melphalan injections during neoadjuvant systemic chemotherapy (carboplatin, vincristine, and etoposide). Patients are eligible if they have unilateral Group D retinoblastoma with vitreous seeding or bilateral retinoblastoma with the worst eye categorized as Group D and vitreous seeding.
Sources: ARET2121 (NCT05504291)
Source: Retinoblastoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: April 3, 2025. Captured 2026-09-09.
Because a proportion of children who present with unilateral retinoblastoma will eventually develop disease in the opposite eye, these children undergo genetic counseling and testing and periodic examinations of the unaffected eye, regardless of the treatment they receive. Asynchronous bilateral disease occurs most frequently in patients with affected parents and in children diagnosed during the first months of life.
Source: Retinoblastoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: April 3, 2025. Captured 2026-09-09.
The goal of therapy for bilateral retinoblastoma is ocular and vision preservation and the delay or avoidance of EBRT and enucleation.
Treatment options for bilateral intraocular retinoblastoma include the following:
Enucleation for large intraocular tumors, followed by pathology-based, risk-adapted chemotherapy when the eye and vision cannot be saved.
Conservative ocular salvage approaches when the eye and vision can be saved:
Conservative ocular salvage approaches when the eye and vision can be saved:
Chemoreduction with either systemic or intra-arterial chemotherapy with or without intravitreal chemotherapy.
Local treatments, including cryotherapy, thermotherapy, and plaque radiation therapy.
EBRT.
Intraocular tumor burden is usually asymmetrical, and treatment is dictated by the most advanced eye. Systemic therapy is generally selected based on the eye with more extensive disease. Treatment options described for unilateral disease may be applied to one or both affected eyes in patients with bilateral disease. While up-front enucleation of an advanced eye and risk-adapted adjuvant chemotherapy may be required, a more conservative approach using primary chemoreduction and aggressive local treatments with close monitoring for response is usually the treatment of choice. EBRT is now reserved for patients whose eyes do not respond adequately to primary systemic or intra-arterial chemotherapy and local consolidation.[20]
Sources: 20
Several large centers have published trial results that used systemic chemotherapy in conjunction with aggressive local consolidation for patients with bilateral disease.[21] The backbone of chemoreduction has generally been carboplatin, etoposide, and vincristine. While the less toxic combination of vincristine and carboplatin can provide disease control for a significant proportion of patients, ocular salvage appears to be superior when etoposide is included in the regimen.[22][Level of evidence B1] A single-institution study achieved similar results when topotecan was substituted for etoposide in a combination regimen.[23][Level of evidence C1] Using chemoreduction and aggressive local control consolidation, the International Classification of Retinoblastoma grouping system has been proven to predict ocular survival, with globe salvage rates usually exceeding 80% for Groups A and B, and 40% to 80% for Groups C and D, although EBRT may be required in more advanced intraocular cases.[24]; [21,23][Level of evidence C1]
Sources: 21 · 22 · Level of evidence B1 · 23 · Level of evidence C1 · 24 · 21 · 23 · Level of evidence C1
Delivery of chemotherapy via ophthalmic artery cannulation with the addition of intra-vitreal chemotherapy for patients with persistent vitreous or subretinal disease has become a very strong alternative to the use of systemic chemotherapy.[13,14,16,17]; [15][Level of evidence C3] While tandem administration is feasible, bilateral administrations increase the risk of systemic toxicity caused by melphalan exposure.[25] In these circumstances, intra-arterial chemotherapy with single-agent carboplatin may be used to treat the less-advanced eye during the tandem procedure.[26] These treatments should only be performed in an experienced center with a state-of-the-art treatment infrastructure and a dedicated multidisciplinary team. For more information, see the sections on Intra-Arterial Chemotherapy (Ophthalmic Artery Infusion of Chemotherapy) and Intravitreal Chemotherapy.
Sources: 13 · 14 · 16 · 17 · 15 · Level of evidence C3 · 25 · 26 · Intra-Arterial Chemotherapy (Ophthalmic Artery Infusion of Chemotherapy) · Intravitreal Chemotherapy
For patients with large intraocular tumor burdens with subretinal or vitreous seeds (Group D eyes), the administration of higher doses of carboplatin coupled with subtenon carboplatin, and the addition of lower doses of EBRT (36 Gy) for patients with persistent disease has been explored. Using this intensive approach, eye survival may approach a rate of 70% at 60 months.[27][Level of evidence B4]
Sources: 27 · Level of evidence B4
The prognosis for patients with Group E eyes who are treated with systemic chemotherapy and local control measures is very poor without radiation therapy.[27][Level of evidence B4] The use of prolonged systemic chemotherapy for Group E eyes to avoid or delay enucleation has been associated with lower disease-specific survival.[12][Level of evidence C1]
Sources: 27 · Level of evidence B4 · 12 · Level of evidence C1
Source: Retinoblastoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: April 3, 2025. Captured 2026-09-09.
Information about National Cancer Institute (NCI)–supported clinical trials can be found on the NCI website. For information about clinical trials sponsored by other organizations, see the ClinicalTrials.gov website.
Sources: NCI website · ClinicalTrials.gov website
The following is an example of a national and/or institutional clinical trial that is currently being conducted:
ARET2121 (NCT05504291) (A Study to Give Treatment Inside the Eye to Treat Retinoblastoma): This trial is exploring the feasibility of incorporating intravitreal melphalan injections during neoadjuvant systemic chemotherapy (carboplatin, vincristine, and etoposide). Patients are eligible if they have unilateral Group D retinoblastoma with vitreous seeding or bilateral retinoblastoma with the worst eye categorized as Group D and vitreous seeding.
Sources: ARET2121 (NCT05504291)
Source: Retinoblastoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: April 3, 2025. Captured 2026-09-09.
In high-income countries, few patients with retinoblastoma present with extraocular disease. Extraocular disease may be localized to the soft tissues surrounding the eye or to the optic nerve beyond the margin of resection. However, further extension may progress into the brain and meninges, with subsequent seeding of the spinal fluid and as distant metastatic disease involving the lungs, bones, and bone marrow.
Source: Retinoblastoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: April 3, 2025. Captured 2026-09-09.
Orbital retinoblastoma occurs as a result of tumor progression through the emissary vessels and sclera. For this reason, transscleral disease is considered to be extraocular and should be treated as such. Orbital retinoblastoma is isolated in 60% to 70% of cases.
Treatment options for extraocular retinoblastoma (orbital and locoregional) include the following:
Chemotherapy.
Radiation therapy.
Enucleation (for extraocular extension).
Treatment includes systemic chemotherapy and radiation therapy. With this treatment approach, 60% to 85% of patients can be cured. Because most recurrences occur in the central nervous system (CNS), regimens that include drugs with well-documented CNS penetration are used.
The Children’s Oncology Group (COG) performed a prospective international trial (ARET0321 [NCT00554788]) that included patients with extraocular retinoblastoma. The study showed that intensified therapy improved the outcomes of patients with stage II, III or IVa disease, compared with historical controls. However, stage IVb patients need more effective therapy.[1][Level of evidence B4]
Sources: ARET0321 [NCT00554788] · 1 · Level of evidence B4
Patients with stage II or III retinoblastoma (n = 19) received four cycles of chemotherapy (vincristine, cisplatin, cyclophosphamide, etoposide) followed by involved-field radiation therapy (45 Gy).
Patients with stage II or III retinoblastoma (n = 19) received four cycles of chemotherapy (vincristine, cisplatin, cyclophosphamide, etoposide) followed by involved-field radiation therapy (45 Gy).
The median follow-up was 7.3 years.
The 3-year event-free survival (EFS) and overall survival (OS) rates were 88.1%.
Patients with stage IVa retinoblastoma (n = 18) received four cycles of induction therapy (noted above). Patients with more than a partial response underwent autologous hematopoietic stem cell support. Patients with residual tumor after chemotherapy received radiation therapy.
Patients with stage IVa retinoblastoma (n = 18) received four cycles of induction therapy (noted above). Patients with more than a partial response underwent autologous hematopoietic stem cell support. Patients with residual tumor after chemotherapy received radiation therapy.
The 3-year EFS and OS rates were 76.7%.
Patients with stage IVb retinoblastoma (n = 20) received the same treatment as patients with stage IVa disease.
Patients with stage IVb retinoblastoma (n = 20) received the same treatment as patients with stage IVa disease.
The 1-year EFS rate was 28.3%, and the OS rate was 42.1%.
The 3-year EFS rate was 14.2%, and the OS rate was 12.3%.
Six patients developed secondary malignancies. There was one case each of osteosarcoma (8 years after treatment), thyroid papillary carcinoma (9 years after treatment), glioblastoma multiforme (8 years after treatment), large B-cell Epstein-Barr virus–associated lymphoproliferative disorder (8 months after treatment), acute myeloid leukemia (2 years after treatment), and alveolar soft part sarcoma of the bladder (5 years after treatment). Five patients had unilateral retinoblastoma, two of whom received radiation therapy (one each with unilateral and bilateral).
For patients with macroscopic orbital disease, delay of surgery until response to chemotherapy is achieved (usually after receiving two or three courses of treatment) has been effective. Patients then undergo enucleation and receive an additional four to six courses of chemotherapy. During consolidation, the patient receives local control therapies with orbital irradiation (40–45 Gy). Using this approach, orbital exenteration is not indicated.[2]
Sources: 2
Patients with isolated involvement of the optic nerve at the transsection level are considered to have extraocular disease and are treated using systemic therapy, similar to that used for macroscopic orbital disease, and irradiation of the entire orbit (36 Gy) with a 10 Gy boost to the chiasm (total of 46 Gy).[3]
Sources: 3
Source: Retinoblastoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: April 3, 2025. Captured 2026-09-09.
Intracranial dissemination occurs by direct extension through the optic nerve. The prognosis for these patients is dismal. Treatment includes platinum-based, intensive systemic chemotherapy and CNS-directed therapy. Although intrathecal chemotherapy has been used traditionally, there is no preclinical or clinical evidence to support its use.
Treatment options for extraocular retinoblastoma (CNS disease) include the following:
Systemic chemotherapy and CNS-directed therapy with radiation therapy.
Systemic chemotherapy followed by myeloablative chemotherapy and stem cell rescue with or without radiation therapy.
The administration of radiation therapy to these patients is controversial. Responses have been observed with craniospinal radiation using 25 Gy to 35 Gy to the entire craniospinal axis and a boost (10 Gy) to sites of measurable disease.[1]
Sources: 1
The COG conducted a prospective study (ARET0321 [NCT00554788]) of patients with extraocular retinoblastoma, which included patients with stage IVb disease who were treated with four cycles of induction therapy (vincristine, cisplatin, cyclophosphamide, and etoposide).[1][Level of evidence B4]
Sources: ARET0321 [NCT00554788] · 1 · Level of evidence B4
Patients who had more than a partial response were then treated with high-dose carboplatin, thiotepa, and etoposide with autologous hematopoietic stem cell support.
Patients with residual disease after chemotherapy received radiation therapy.
In the 20 patients with stage IVb disease, the 1-year EFS rate was 28.3%, and the OS rate was 42.1%. The 3-year EFS rate was 14.2%, and the OS rate was 12.3%.
Source: Retinoblastoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: April 3, 2025. Captured 2026-09-09.
Trilateral retinoblastoma is usually associated with a pineal lesion or, less commonly, a suprasellar lesion.[4-6] In patients with the heritable form of retinoblastoma, CNS disease is less likely the result of metastatic or regional spread than of a primary intracranial focus, such as a pineal tumor. The prognosis for patients with trilateral retinoblastoma is very poor. Most patients die of disseminated neuraxis disease in less than 9 months.[7,8] However, with increased surveillance and aggressive therapy, there has been improvement in survival, from 6% (patients treated before 1995) to 44% (patients treated after 1996).[9]
Treatment options for synchronous trilateral retinoblastoma include the following:
Systemic chemotherapy followed by surgery and myeloablative chemotherapy with stem cell rescue.
Systemic chemotherapy followed by surgery and radiation therapy.
While pineoblastomas occurring in older patients are sensitive to radiation therapy, current strategies are directed towards avoiding radiation by using intensive chemotherapy followed by consolidation with myeloablative chemotherapy and autologous hematopoietic progenitor cell rescue. This approach is similar to those being used in the treatment of brain tumors in infants.[10]
Sources: 10
For more information about trilateral retinoblastoma, including screening with neuroimaging, see the Trilateral retinoblastoma section.
Sources: Trilateral retinoblastoma
Source: Retinoblastoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: April 3, 2025. Captured 2026-09-09.
Treatment options for extracranial metastatic retinoblastoma include the following:
Systemic chemotherapy followed by myeloablative chemotherapy with stem cell rescue and radiation therapy.
Hematogenous metastases may develop in the bones, bone marrow, and, less frequently, the liver. The COG conducted a prospective international trial (ARET0321 [NCT00554788]) for patients with extraocular retinoblastoma. The study showed that intensified therapy improved the outcomes of patients with stage IVa disease.[1][Level of evidence B4] Patients with stage IVa retinoblastoma (n = 18) were treated with four cycles of induction therapy (vincristine, cisplatin, cyclophosphamide, and etoposide).
Sources: ARET0321 [NCT00554788] · 1 · Level of evidence B4
The patients who had more than a partial response then received one cycle of high-dose carboplatin, thiotepa, and etoposide with autologous hematopoietic stem cell support. Patients with residual tumor after chemotherapy received radiation therapy.
With a median follow up of 7.3 years, the 3-year EFS and OS rates were 76.7%.
Source: Retinoblastoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: April 3, 2025. Captured 2026-09-09.
The prognosis for a patient with progressive or recurrent retinoblastoma depends on the site and extent of the progression or recurrence and previous treatment received.
The introduction of intravenous chemotherapy for the treatment of retinoblastoma in the early 1990s revolutionized retinoblastoma management. In a retrospective review of 869 eyes in 551 patients with retinoblastoma who were treated with chemoreduction, 64% of the eyes experienced a recurrence and 94% of the recurrences or new tumors were detected within the first 3 years of treatment. Risk factors for recurrence included the following:[1][Level of evidence C1]
Sources: 1 · Level of evidence C1
Younger patient age at diagnosis (odds ratio [OR], 1.02 per 1 month decrease; P = .02).
More advanced International Classification of Retinoblastoma group (OR, 1.24 per 1 more advanced group; P = .01).
Closer tumor distance to the optic disc (OR, 1.11 per 1 mm decrease; P = .03).
Presentation with subretinal seeds (OR, 1.66; P = .02).
Presence of germline pathogenic variants, which contributed to the risk of new tumor formation.
Intraocular and extraocular recurrences have very different prognoses and are treated in different ways.
Source: Retinoblastoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: April 3, 2025. Captured 2026-09-09.
Treatment options for progressive or recurrent intraocular retinoblastoma include the following:
Enucleation.
Radiation therapy (external-beam or plaque radiation therapy).
Local treatments (cryotherapy or thermotherapy).
Salvage chemotherapy (systemic or intra-arterial chemotherapy).
Intravitreal chemotherapy, especially for refractory or recurrent vitreous seeding.
For more information about the use and potential applications of intra-arterial and intravitreal chemotherapy, see the sections on Intra-Arterial Chemotherapy (Ophthalmic Artery Infusion of Chemotherapy) and Intravitreal Chemotherapy.
Sources: Intra-Arterial Chemotherapy (Ophthalmic Artery Infusion of Chemotherapy) · Intravitreal Chemotherapy
New intraocular tumors can arise in patients with the heritable form of disease whose eyes have been treated with local control measures only because every cell in the retina carries the RB1 variant. This event should not be considered a recurrence. Even with previous treatment consisting of chemoreduction and local control measures in very young patients with heritable retinoblastoma, surveillance may detect new tumors at an early stage. Additional local control therapy, including plaque radiation therapy, can successfully eradicate these tumors.[2]
Sources: 2
When the recurrence or progression of retinoblastoma is confined to the eye and is small, the prognosis for sight and survival may be excellent with local therapy only.[3][Level of evidence C3] If the recurrence or progression is confined to the eye but is extensive, the prognosis for sight is poor; however, survival remains excellent.
Sources: 3 · Level of evidence C3
Intra-arterial chemotherapy (IAC) into the ophthalmic artery has been effective in patients who relapse after systemic chemotherapy and radiation therapy.[4,5] Rescue IAC, usually with other agents, has also been used after primary IAC.[6] Plaque radiation therapy is an option for patients who have a retinoblastoma recurrence after IAC treatment.[7][Level of evidence C3] Radiation therapy should be considered for patients who have not been previously irradiated. Finally, enucleation may be required in cases of progressive disease after all eye-salvaging treatments have failed.
Sources: 4 · 5 · 6 · 7 · Level of evidence C3
Source: Retinoblastoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: April 3, 2025. Captured 2026-09-09.
Treatment options for progressive or recurrent extraocular retinoblastoma include the following:
Systemic chemotherapy and radiation therapy for orbital disease.
Systemic chemotherapy followed by myeloablative chemotherapy with stem cell rescue and radiation therapy for extraorbital disease.
Recurrence in the orbit after enucleation is treated with aggressive chemotherapy in addition to local radiation therapy because of the high risk of metastatic disease.[8][Level of evidence C1] After enucleation for recurrence, high-resolution magnetic resonance imaging with orbital coils can be helpful in distinguishing orbital recurrence from postsurgical enhancement.[9]
Sources: 8 · Level of evidence C1 · 9
If the recurrence or progression is extraocular, the chance of survival is poor.[10] However, the use of intensive systemic chemotherapy and consolidation with high-dose chemotherapy and autologous hematopoietic stem cell rescue may improve the chance of a cure, particularly for patients with extracranial recurrence. For patients with disease recurrence after those intensive approaches, clinical trials may be considered. For more information, see the Treatment of Extraocular Retinoblastoma section.
Sources: 10 · Treatment of Extraocular Retinoblastoma
Source: Retinoblastoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: April 3, 2025. Captured 2026-09-09.
One approach under investigation for patients with progressive intraocular retinoblastoma includes the use of an oncolytic adenovirus that targets RB1.[11]
Sources: 11
Information about National Cancer Institute (NCI)–supported clinical trials can be found on the NCI website. For information about clinical trials sponsored by other organizations, see the ClinicalTrials.gov website.
Sources: NCI website · ClinicalTrials.gov website
Source: Retinoblastoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: April 3, 2025. Captured 2026-09-09.
In a report from the Retinoblastoma Survivor Study (N = 470), 87% of survivors of retinoblastoma (mean age, 43 years; median follow-up, 42 years) had at least one medical condition and 71% had a severe or life-threatening condition. Compared with patients without retinoblastoma, the adjusted relative risk of a chronic condition in survivors was 1.4 (P < .01). The relative risk of a grade 3 or 4 condition was 7.6 (P < .01). After excluding ocular conditions and subsequent neoplasms (SNs), this excess risk was found to persist only for patients with bilateral disease.[1]
Sources: 1
Source: Retinoblastoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: April 3, 2025. Captured 2026-09-09.
SNs are the most common cause of death in patients with retinoblastoma. SNs contribute to about 50% of deaths in patients with both bilateral disease and genetically defined heritable retinoblastoma.[2-4] Survivors of retinoblastoma have a high risk of developing SNs.
Factors that influence the risk of SNs include the following:
Heritable retinoblastoma. Patients with heritable retinoblastoma have a markedly increased incidence of SNs, independent of treatment with radiation therapy.[2,3,5] In a German series of 643 patients with heritable retinoblastoma, chemotherapy with or without radiation therapy was the only significant risk factor for the onset of second cancers outside the periorbital region.[3] A possible association between the type of RB1 variant and incidence of SNs may exist, with complete loss of RB1 activity associated with a higher incidence of SNs.[6] Patients who are heterozygous for regular-penetrance RB1 variants may be at a higher risk of developing SNs than patients with incomplete-penetrance RB1 variants.[7] Regular penetrance refers to patients with heritable disease and classic multifocal bilateral tumors. Incomplete penetrance, while rare, is a clinical phenotype in which affected family members may not develop retinoblastoma or they present with unilateral disease. With the increase in survival of patients with heritable retinoblastoma, it has become apparent that they are also at risk of developing epithelial cancers late in adulthood. A marked increase in mortality from lung, bladder, and other epithelial cancers has been described.[8,9]In a large series from two institutions, 2,053 patients with retinoblastoma (diagnosed between 1914–2016) were identified, with a maximum of 70 years of follow-up. Most deaths occurred in patients with hereditary retinoblastoma (518 of 1,129), and 267 of these deaths were caused by SNs. Increased risk of death resulting from cancers of the pancreas, large intestines, and kidney were reported. Overall risk of SNs was greater for patients who were treated with radiation therapy and chemotherapy compared with patients who were treated with radiation therapy alone, although patterns varied by organ site. In a cohort of 143 retinoblastoma survivors diagnosed between 1997 and 2006, continued improvements in mortality were seen.[4][Level of evidence C1] For patients with nonhereditary retinoblastoma, only 27 deaths in 924 patients were attributed to SNs. Among retinoblastoma survivors with heritable retinoblastoma, those with an inherited germline pathogenic variant are at a slightly higher risk of developing an SN than are those with a de novo variant. Melanoma was the most common SN seen in patients with germline pathogenic variants.[10]
Sources: 2 · 3 · 5 · 3 · 6 · 7 · 8 · 9 · 4 · Level of evidence C1 · 10
Past treatment for retinoblastoma with radiation therapy. The cumulative incidence of SNs was reported to be 26% (± 10%) in nonirradiated patients and 58% (± 10%) in irradiated patients by 50 years after diagnosis of retinoblastoma, resulting in a rate of about 1% per year.[11]A German series of 633 patients with heritable retinoblastoma demonstrated a 5-year survival rate of 93%. However, 40 years later, only 80% of patients survived, with most succumbing to radiation-induced SNs (hazard ratio, approximately 3).[12] Other studies analyzing cohorts of patients treated with more advanced radiation planning and delivery technology have reported the SN rates to be about 9.4% in nonirradiated patients and about 30.4% in irradiated patients.[13] In a nonrandomized study that compared two contemporary cohorts of patients with hereditary retinoblastoma who were treated with either photon (n = 31) or proton (n = 55) therapy, the 10-year cumulative incidence of radiation-induced SNs was significantly different between the two groups (0% for proton radiation vs. 14% for photon radiation; P = .015).[14] Longer follow-up is required to further define the risk of SNs associated with proton radiation.The most common SN is sarcoma, specifically osteosarcoma, followed by soft tissue sarcoma and melanoma. These malignancies may occur inside or outside of the radiation field, although most are radiation induced. The carcinogenic effect of radiation therapy is associated with the dose delivered, particularly for subsequent sarcomas. A step-wise increase is apparent at all dose categories. In irradiated patients, two-thirds of SNs occur within irradiated tissue, and one-third of SNs occur outside the radiation field.[5,11,13,15] In a cohort of 952 irradiated survivors of hereditary retinoblastoma who were originally diagnosed between 1914 and 2006, 105 bone sarcomas and 125 soft tissue sarcomas were identified. Approximately two-thirds of these cancers occurred in the head and neck. The incidence rates were 2,000-fold higher for bone sarcomas and 500-fold higher for soft tissue sarcomas than was expected in the general population. Head and neck bone and soft tissue sarcomas were diagnosed in early childhood and continued into adulthood, with a 60-year cumulative incidence of 6.8% for bone sarcomas and 9.3% for soft tissue sarcomas. Bone and soft tissue sarcomas diagnosed elsewhere in the body were increased 169-fold and 45.7-fold, respectively, compared with the general population. Bone sarcomas primarily occurred in the long bones during adolescence. The incidence of soft tissue sarcomas was rare until age 30 years, when it rose steeply (60-year cumulative incidence, 6.6%), particularly for females (9.4%). The soft tissue sarcomas that occurred in females were leiomyosarcomas and were mainly located in the abdomen and pelvis.[5,11]; [16][Level of evidence C1]
Sources: 11 · 12 · 13 · 14 · 5 · 11 · 13 · 15 · 5 · 11 · 16 · Level of evidence C1
Age at time of radiation therapy. The risk of SNs also appears to depend on the patient's age at the time that external-beam radiation therapy (EBRT) is administered, especially in children younger than 12 months. The histopathological types of SNs may be influenced by age.[13,17,18]
Previous SN. Patients who survive SNs are at a sevenfold increased risk of developing another SN.[19] The risk increases an additional threefold for patients treated with radiation therapy.[20]
The issue of balancing long-term tumor control with the consequences of chemotherapy is unresolved. Most patients who receive chemotherapy are exposed to etoposide, which has been associated with secondary leukemia in patients without a predisposition to cancer. However, most patients are exposed at modest rates when compared with the risks associated with EBRT in heritable retinoblastoma.
Despite the known increased risk of acute myeloid leukemia (AML) associated with the use of etoposide, patients with heritable retinoblastoma are not at an increased risk of developing this SN.[21-23] An initial report conducted by informal survey methods described 15 patients who developed AML after chemotherapy. One-half of the patients also received radiation therapy.[22] This finding has not been substantiated by formal studies. In a single-institution study of 245 patients who received etoposide, only 1 patient developed acute promyelocytic leukemia after 79 months.[21] Additionally, the Surveillance, Epidemiology, and End Results (SEER) Program calculated standardized incidence rates for secondary hematopoietic malignancies in 34,867 survivors of childhood cancer. The observed-to-expected ratio of secondary AML in patients treated for retinoblastoma was zero.[24]
Source: Retinoblastoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: April 3, 2025. Captured 2026-09-09.
Other late effects that may occur after treatment for retinoblastoma include the following:
Diminished orbital growth. Orbital growth is somewhat diminished after enucleation. However, the impact of enucleation on orbital volume may be minimized after placement of an orbital implant.[31] Asymmetry of orbital size that develops after enucleation is greater in younger children and infants, but enucleation after age 3 years does not result in orbital asymmetry.[32]
Visual-field deficits. Patients with retinoblastoma demonstrate a variety of long-term visual-field defects after treatment for their intraocular disease. These defects are related to tumor size, location, and treatment method.[33] One study of visual acuity after treatment with systemic chemotherapy and local ophthalmic therapy was conducted in 54 eyes of 40 children. After a mean follow-up of 68 months, 27 eyes (50%) had a final visual acuity of 20/40 or better, and 36 eyes (67%) had a final visual acuity of 20/200 or better. The clinical factors that predicted visual acuity of 20/40 or better were a tumor margin of at least 3 mm from the foveola and optic disc and an absence of subretinal fluid.[34]
Strabismus. In a study of 42 survivors of retinoblastoma (64 eyes) who underwent successful conservative treatment, 69% of patients were noted to have strabismus at final follow-up (mean, 93.7 months). Exotropia was the most common type of strabismus reported. Conservative treatments included intravenous chemotherapy (62 eyes), intra-arterial chemotherapy (10 eyes), brachytherapy (11 eyes), transpupillary thermotherapy (22 eyes), cryotherapy (47 eyes), and external-beam radiation therapy (4 eyes). On multivariate analysis, only foveal involvement was found to be a significant risk factor for developing strabismus (P < .001).[35]
Sources: 35
Hearing loss. Because systemic carboplatin is now commonly used in the treatment of retinoblastoma, concern has been raised about hearing loss related to therapy. For more information about treatment, see the sections on Treatment of Intraocular Retinoblastoma and Treatment of Extraocular Retinoblastoma. While two large studies that included children treated with six cycles of carboplatin-containing therapy (18.6 mg/kg per cycle) showed an incidence of treatment-related hearing loss of lower than 1%,[36,37] a separate series documented some degree of hearing loss in 17% of patients.[38] In the latter study, younger age (younger than 6 months at the time of treatment) and higher carboplatin systemic exposures correlated with an increased risk of ototoxicity.[38,39]
Sources: Treatment of Intraocular Retinoblastoma · Treatment of Extraocular Retinoblastoma · 36 · 37 · 38 · 38 · 39
Neurocognitive functioning. Early studies of intellectual functioning in survivors of retinoblastoma suggested above average intelligence among survivors of bilateral disease compared with unaffected siblings and the general population, especially in those who were blind as a result of their disease.[40-42] Later studies have yielded mixed results with conflicting findings, in part, resulting from the low test-retest reliability of measures used to assess cognitive outcomes at a very young age, as well as temporal differences in treatment exposures.
Neurocognitive functioning. Early studies of intellectual functioning in survivors of retinoblastoma suggested above average intelligence among survivors of bilateral disease compared with unaffected siblings and the general population, especially in those who were blind as a result of their disease.[40-42] Later studies have yielded mixed results with conflicting findings, in part, resulting from the low test-retest reliability of measures used to assess cognitive outcomes at a very young age, as well as temporal differences in treatment exposures.
Serial assessment of cognitive and adaptive functioning in a group of survivors younger than 6 years revealed declines in developmental functioning over time, with the most pronounced declines observed in patients with 13q deletions.[43]
Sources: 43
Neurocognitive functioning. Early studies of intellectual functioning in survivors of retinoblastoma suggested above average intelligence among survivors of bilateral disease compared with unaffected siblings and the general population, especially in those who were blind as a result of their disease.[40-42] Later studies have yielded mixed results with conflicting findings, in part, resulting from the low test-retest reliability of measures used to assess cognitive outcomes at a very young age, as well as temporal differences in treatment exposures. › Serial assessment of cognitive and adaptive functioning in a group of survivors younger than 6 years revealed declines in developmental functioning over time, with the most pronounced declines observed in patients with 13q deletions.[43]
Further longitudinal follow-up of this cohort identified improvement in adaptive functioning in all treatment groups and improvement in cognitive functioning in survivors who were treated with enucleation alone between the ages of 5 years and 10 years.[44]
Sources: 44
At age 10 years, overall functioning was generally within the average range, although estimated intelligence quotient was significantly below the normative mean for children who were treated with enucleation alone.[44]
Sources: 44
Neurocognitive functioning. Early studies of intellectual functioning in survivors of retinoblastoma suggested above average intelligence among survivors of bilateral disease compared with unaffected siblings and the general population, especially in those who were blind as a result of their disease.[40-42] Later studies have yielded mixed results with conflicting findings, in part, resulting from the low test-retest reliability of measures used to assess cognitive outcomes at a very young age, as well as temporal differences in treatment exposures.
A study of very long-term adult survivors of retinoblastoma, who were on average 33 years postdiagnosis, demonstrated largely average cognitive functioning across domains of intelligence, memory, attention, and executive function.[45]
Sources: 45
For specific information about the incidence, type, and monitoring of late effects in childhood and adolescent cancer survivors, see Late Effects of Treatment for Childhood Cancer.
Source: Retinoblastoma Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: October 7, 2021. Captured 2026-09-09.
The prognosis and treatment options depend on the following:
Sources: prognosis
Whether the cancer is in one or both eyes.
The size and number of tumors.
Whether the tumor has spread to the area around the eye, to the brain, or to other parts of the body.
The age of the child.
How likely it is that vision can be saved in one or both eyes.
Whether a second type of cancer has formed.
Whether the cancer is newly diagnosed or has recurred (come back).
Sources: recurred
Source: Retinoblastoma Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: October 7, 2021. Captured 2026-09-09.
Source: Retinoblastoma Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: October 7, 2021. Captured 2026-09-09.
In intraocular retinoblastoma, cancer is found in one or both eyes and may be in the retina only or may also be in other parts of the eye such as the choroid, ciliary body, or part of the optic nerve. Cancer has not spread to tissues around the outside of the eye or to other parts of the body.
Sources: intraocular · retinoblastoma · cancer · retina · choroid · ciliary body · optic nerve · tissues
Source: Retinoblastoma Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: October 7, 2021. Captured 2026-09-09.
In extraocular retinoblastoma, cancer has spread beyond the eye. It may be found in tissues around the eye (orbital retinoblastoma), or it may have spread to the central nervous system (brain and spinal cord) or to other parts of the body such as the liver, bone, bone marrow, or lymph nodes.
Sources: extraocular · retinoblastoma · cancer · tissues · central nervous system · liver · bone marrow · lymph nodes
Source: Retinoblastoma Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: October 7, 2021. Captured 2026-09-09.
Progressive retinoblastoma is cancer that continues to grow, spread or get worse. Progressive disease may be a sign that the cancer has become refractory to treatment.
Sources: Progressive · retinoblastoma · refractory
Source: Retinoblastoma Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: October 7, 2021. Captured 2026-09-09.
Source: Retinoblastoma Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: October 7, 2021. Captured 2026-09-09.
There are different types of treatment for patients with retinoblastoma.
Children with retinoblastoma should have their treatment planned by a team of health care providers who are experts in treating cancer in children.
Six types of standard treatment are used:
Six types of standard treatment are used:
Cryotherapy
Thermotherapy
Chemotherapy
Radiation therapy
High-dose chemotherapy with stem cell rescue
Surgery (enucleation)
New types of treatment are being tested in clinical trials.
New types of treatment are being tested in clinical trials.
Targeted therapy
Treatment for retinoblastoma may cause side effects.
Patients may want to think about taking part in a clinical trial.
Patients can enter clinical trials before, during, or after starting their cancer treatment.
Follow-up tests may be needed.
Source: Retinoblastoma Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: October 7, 2021. Captured 2026-09-09.
Different types of treatment are available for patients with retinoblastoma. Some treatments are standard (the currently used treatment), and some are being tested in clinical trials. A treatment clinical trial is a research study meant to help improve current treatments or obtain information on new treatments for patients with cancer. When clinical trials show that a new treatment is better than the standard treatment, the new treatment may become the standard treatment.
Sources: retinoblastoma · standard · clinical trials · research study · cancer
Because cancer in children is rare, taking part in a clinical trial should be considered. Some clinical trials are open only to patients who have not started treatment.
Source: Retinoblastoma Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: October 7, 2021. Captured 2026-09-09.
The goals of treatment are to save the child's life, to save vision and the eye, and to prevent serious side effects. Treatment will be overseen by a pediatric oncologist, a doctor who specializes in treating children with cancer. The pediatric oncologist works with other health care providers who are experts in treating children with eye cancer and who specialize in certain areas of medicine. These may include a pediatric ophthalmologist (children's eye doctor) who has a lot of experience in treating retinoblastoma and the following specialists:
Sources: side effects · pediatric oncologist · health care providers · eye cancer · medicine · pediatric · ophthalmologist · specialists
Pediatric surgeon.
Sources: Pediatric surgeon
Radiation oncologist.
Sources: Radiation oncologist
Pediatrician.
Sources: Pediatrician
Pediatric nurse specialist.
Sources: Pediatric nurse specialist
Rehabilitation specialist.
Sources: Rehabilitation specialist
Social worker.
Sources: Social worker
Geneticist or genetic counselor.
Sources: Geneticist · genetic counselor
Source: Retinoblastoma Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: October 7, 2021. Captured 2026-09-09.
Source: Retinoblastoma Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: October 7, 2021. Captured 2026-09-09.
Cryotherapy is the use of extreme cold to destroy abnormal tissue. A small metal probe is cooled below freezing and placed on the surface of the eye near the tumor, which freezes and kills cancer cells. Cryotherapy is usually used to treat small retinoblastoma tumors that are located toward the front of the eye. This type of treatment is also called cryosurgery.
Sources: Cryotherapy · abnormal · tissue · tumor · cells
Source: Retinoblastoma Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: October 7, 2021. Captured 2026-09-09.
Thermotherapy is the use of heat to destroy cancer cells. Thermotherapy may be given using a laser beam aimed through the dilated pupil or onto the outside of the eyeball. Thermotherapy may be used alone for small tumors or combined with chemotherapy for larger tumors. This treatment is a type of laser therapy.
Sources: Thermotherapy · cells · laser · dilated · pupil · tumors · chemotherapy · laser therapy
Source: Retinoblastoma Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: October 7, 2021. Captured 2026-09-09.
Chemotherapy is a cancer treatment that uses drugs to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. The way the chemotherapy is given depends on the stage of the cancer and where the cancer is in the body.
There are different types of chemotherapy:
Systemic chemotherapy: When chemotherapy is taken by mouth or injected into a vein or muscle, the drugs enter the bloodstream and can reach cancer cells throughout the body. Systemic chemotherapy is given to shrink the tumor (chemoreduction) and avoid surgery to remove the eye. After chemoreduction, other treatments may include radiation therapy, cryotherapy, laser therapy, or regional chemotherapy. However, extraorbital disease requires intensive chemotherapy and may include consolidation with high-dose chemotherapy and autologous stem cell transplantation with or without radiation therapy.Systemic chemotherapy may also be given to kill any cancer cells that are left after the initial treatment or to kill cancer cells that are outside the eye. Treatment given after the initial treatment, to lower the risk that the cancer will come back, is called adjuvant therapy.
Sources: Systemic chemotherapy · injected · vein · chemoreduction · radiation therapy · regional chemotherapy · intensive chemotherapy · high-dose chemotherapy · autologous stem cell transplantation · adjuvant therapy
Regional chemotherapy: When chemotherapy is placed directly into the cerebrospinal fluid (intrathecal chemotherapy), an organ (such as the eye), or a body cavity, the drugs mainly affect cancer cells in those areas. Several types of regional chemotherapy are used to treat retinoblastoma.
Sources: cerebrospinal fluid · intrathecal chemotherapy · organ · cavity
Regional chemotherapy: When chemotherapy is placed directly into the cerebrospinal fluid (intrathecal chemotherapy), an organ (such as the eye), or a body cavity, the drugs mainly affect cancer cells in those areas. Several types of regional chemotherapy are used to treat retinoblastoma.
Ophthalmic artery infusion chemotherapy: Ophthalmic artery infusion chemotherapy carries anticancer drugs directly to the eye. A catheter is put into an artery that leads to the eye and the anticancer drug is given through the catheter. After the drug is given, a small balloon may be inserted into the artery to block it and keep most of the anticancer drug trapped near the tumor. This type of chemotherapy may be given as the initial treatment when the tumor is in the eye only or when the tumor has not responded to other types of treatment. Ophthalmic artery infusion chemotherapy is given at special retinoblastoma treatment centers.
Sources: Ophthalmic artery infusion · catheter · artery
Intravitreal chemotherapy: Intravitreal chemotherapy is the injection of anticancer drugs directly into the vitreous humor (jelly-like substance) inside of the eye. It is used to treat cancer that has spread to the vitreous humor and has not responded to treatment or has come back after treatment.
Sources: Intravitreal chemotherapy · injection · vitreous humor
Intrathecal chemotherapy: Intrathecal chemotherapy is the injection of anticancer drugs directly into the cerebrospinal fluid (CSF). It is used to treat cancer that has spread to the brain.
Sources: Intrathecal chemotherapy · cerebrospinal fluid · brain
See Drugs Approved for Retinoblastoma for more information.
Sources: Drugs Approved for Retinoblastoma
Source: Retinoblastoma Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: October 7, 2021. Captured 2026-09-09.
Radiation therapy is a cancer treatment that uses high-energy x-rays or other types of radiation to kill cancer cells or keep them from growing. There are two types of radiation therapy:
External-beam radiation therapy uses a machine outside the body to send radiation toward the area of the body with cancer. Certain ways of giving radiation therapy can help keep radiation from damaging nearby healthy tissue. These types of radiation therapy include the following:
Sources: External-beam radiation therapy
External-beam radiation therapy uses a machine outside the body to send radiation toward the area of the body with cancer. Certain ways of giving radiation therapy can help keep radiation from damaging nearby healthy tissue. These types of radiation therapy include the following:
Intensity-modulated radiation therapy (IMRT): IMRT is a type of 3-dimensional (3-D) external radiation therapy that uses a computer to make pictures of the size and shape of the tumor. Thin beams of radiation of different intensities (strengths) are aimed at the tumor from many angles.
Sources: Intensity-modulated radiation therapy · 3-dimensional
Proton beam radiation therapy: Proton beam radiation therapy is a type of high-energy, external radiation therapy that uses streams of protons (tiny particles with a positive charge) to kill tumor cells. This type of treatment can lower the amount of radiation damage to healthy tissue near a tumor.
Sources: Proton beam radiation therapy · protons
Internal radiation therapy uses a radioactive substance sealed in needles, seeds, wires, or catheters that are placed directly into or near the cancer. Certain ways of giving radiation therapy can help keep radiation from damaging nearby healthy tissue. This type of internal radiation therapy may include the following:
Sources: Internal radiation therapy · radioactive · seeds · catheters
Internal radiation therapy uses a radioactive substance sealed in needles, seeds, wires, or catheters that are placed directly into or near the cancer. Certain ways of giving radiation therapy can help keep radiation from damaging nearby healthy tissue. This type of internal radiation therapy may include the following:
Plaque radiotherapy: Radioactive seeds are attached to one side of a disk, called a plaque, and placed directly on the outside wall of the eye near the tumor. The side of the plaque with the seeds on it faces the eyeball, aiming radiation at the tumor. The plaque helps protect other nearby tissue from the radiation.
Sources: Plaque radiotherapy
Whether internal or external radiation therapy is given depends on the stage of the cancer being treated, where it is found in the body, and how the cancer responded to other treatments.
Source: Retinoblastoma Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: October 7, 2021. Captured 2026-09-09.
High doses of chemotherapy are given to kill cancer cells. Healthy cells, including blood-forming cells, are also destroyed by the cancer treatment. Stem cell rescue is a treatment to replace the blood-forming cells. Stem cells (immature blood cells) are removed from the blood or bone marrow of the patient and are frozen and stored. After the patient completes chemotherapy, the stored stem cells are thawed and given back to the patient through an infusion. These reinfused stem cells grow into (and restore) the body's blood cells. Extraorbital disease requires intensive chemotherapy and may include consolidation with high-dose chemotherapy and autologous stem cell transplantation with or without radiation therapy.
Sources: doses · blood · Stem cell rescue · Stem cells · bone marrow · infusion
See Drugs Approved for Retinoblastoma for more information.
Sources: Drugs Approved for Retinoblastoma
Source: Retinoblastoma Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: October 7, 2021. Captured 2026-09-09.
Enucleation is surgery to remove the eye and part of the optic nerve. A sample of the eye tissue that is removed will be checked under a microscope to see if there are any signs that the cancer is likely to spread to other parts of the body. This should be done by an experienced pathologist, who is familiar with retinoblastoma and other diseases of the eye. Enucleation is done if there is little or no chance that vision can be saved and when the tumor is large, did not respond to treatment, or comes back after treatment. The patient will be fitted for an artificial eye.
Sources: Enucleation · surgery · optic nerve · microscope · signs · pathologist · tumor · respond
Close follow-up is needed for 2 years or more to check for signs of recurrence in the area around the affected eye and to check the other eye.
Sources: recurrence
Source: Retinoblastoma Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: October 7, 2021. Captured 2026-09-09.
This summary section describes treatments that are being studied in clinical trials. It may not mention every new treatment being studied. Information about clinical trials is available from the NCI website.
Sources: NCI website
Source: Retinoblastoma Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: October 7, 2021. Captured 2026-09-09.
Targeted therapy is a type of treatment that uses drugs or other substances to identify and attack specific cancer cells. Targeted therapies usually cause less harm to normal cells than chemotherapy or radiation therapy do.
Sources: Targeted therapy
Oncolytic virus therapy: This treatment uses a virus that infects and breaks down cancer cells but not normal cells. An oncolytic adenovirus targeting the RB1 gene is injected into the tumor and may have anticancer effects in retinoblastoma. Targeted therapy is being studied for the treatment of retinoblastoma that has progressed or red.
Sources: Oncolytic virus therapy · virus · adenovirus · gene · progressed · red
Source: Retinoblastoma Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: October 7, 2021. Captured 2026-09-09.
To learn more about side effects that begin during treatment for cancer, visit Side Effects.
Sources: side effects · Side Effects
Side effects from cancer treatment that begin after treatment and continue for months or years are called late effects. Late effects of treatment for retinoblastoma may include the following:
Sources: Side effects · late effects
Physical problems such as seeing or hearing problems.
If the eye is removed, there may be changes in the shape and size of the bone around the eye until an artificial eye is fitted. This is most likely to occur in children aged younger than 3 years.
Changes in mood, feelings, thinking, learning, or memory.
Second cancers (new types of cancer), such as lung and bladder cancers, osteosarcoma, soft tissue sarcoma, or melanoma.
Sources: Second cancers · lung · bladder cancers · osteosarcoma · soft tissue sarcoma · melanoma
The following risk factors may increase the risk of having a second cancer:
Sources: risk factors
Having the heritable form of retinoblastoma.
Sources: heritable
Past treatment with radiation therapy, especially before age 1 year.
Having already had a previous second cancer.
It is important to talk with your child's doctors about the effects cancer treatment can have on your child. Regular follow-up by health professionals who are experts in diagnosing and treating late effects is important. See the PDQ summary on Late Effects of Treatment for Childhood Cancer for more information.
Sources: follow-up · diagnosing · PDQ · Late Effects of Treatment for Childhood Cancer
Source: Retinoblastoma Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: October 7, 2021. Captured 2026-09-09.
For some patients, taking part in a clinical trial may be the best treatment choice. Clinical trials are part of the cancer research process. Clinical trials are done to find out if new cancer treatments are safe and effective or better than the standard treatment.
Sources: clinical trial · standard treatment
Many of today's standard treatments for cancer are based on earlier clinical trials. Patients who take part in a clinical trial may receive the standard treatment or be among the first to receive a new treatment.
Patients who take part in clinical trials also help improve the way cancer will be treated in the future. Even when clinical trials do not lead to effective new treatments, they often answer important questions and help move research forward.
Source: Retinoblastoma Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: October 7, 2021. Captured 2026-09-09.
Some clinical trials only include patients who have not yet received treatment. Other trials test treatments for patients whose cancer has not gotten better. There are also clinical trials that test new ways to stop cancer from recurring (coming back) or reduce the side effects of cancer treatment.
Sources: side effects
Clinical trials are taking place in many parts of the country. Information about clinical trials supported by NCI can be found on NCI’s clinical trials search webpage. Clinical trials supported by other organizations can be found on the ClinicalTrials.gov website.
Sources: clinical trials search · ClinicalTrials.gov
Source: Retinoblastoma Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: October 7, 2021. Captured 2026-09-09.
As your child goes through treatment, they will have follow-up tests or check-ups. Some tests that were done to diagnose or stage the cancer may be repeated to see how well the treatment is working. Decisions about whether to continue, change, or stop treatment may be based on the results of these tests.
Some of the tests will continue to be done from time to time after treatment has ended. The results of these tests can show if your child's condition has changed or if the cancer has recurred (come back).
In retinoblastoma, new tumors may form for a few years after treatment. Regular eye exams are done to check for tumors in both eyes. Children with the heritable form of retinoblastoma will also have imaging tests to check whether cancer has spread to the brain.
Source: Retinoblastoma Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: October 7, 2021. Captured 2026-09-09.
For information about the treatments listed below, see the Treatment Option Overview section.
Sources: Treatment Option Overview
If it is likely that the eye can be saved, treatment may include the following:
Systemic chemotherapy or ophthalmic artery infusion chemotherapy, with or without intravitreal chemotherapy, to shrink the tumor. This may be followed by one or more of the following:
Sources: Systemic chemotherapy · ophthalmic artery infusion · chemotherapy · intravitreal chemotherapy · tumor
Systemic chemotherapy or ophthalmic artery infusion chemotherapy, with or without intravitreal chemotherapy, to shrink the tumor. This may be followed by one or more of the following:
Cryotherapy.
Sources: Cryotherapy
Thermotherapy.
Sources: Thermotherapy
Plaque radiotherapy.
Sources: Plaque radiotherapy
External-beam radiation therapy for bilateral intraocular retinoblastoma that does not respond to other treatments.
Sources: External-beam radiation therapy · bilateral · intraocular · retinoblastoma · respond
If the tumor is large and it is not likely that the eye can be saved, treatment may include the following:
Surgery (enucleation). After surgery, systemic chemotherapy may be given to lower the risk that the cancer will spread to other parts of the body.
Sources: Surgery · enucleation · cancer
When retinoblastoma is in both eyes, the treatment for each eye may be different, depending on the size of the tumor and whether it is likely that the eye can be saved. The dose of systemic chemotherapy is usually based on the eye that has more cancer.
Sources: dose
Patients with cavitary retinoblastoma respond well to treatment and have favorable long-term outcomes, similar to patients with noncavitary retinoblastoma.
Source: Retinoblastoma Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: October 7, 2021. Captured 2026-09-09.
For information about the treatments listed below, see the Treatment Option Overview section.
Sources: Treatment Option Overview
Treatment of extraocular retinoblastoma (cancer has spread to the area around the eye) may include the following:
Sources: extraocular · retinoblastoma
Systemic chemotherapy and external-beam radiation therapy.
Sources: Systemic chemotherapy · external-beam radiation therapy
Enucleation.
Sources: Enucleation
Systemic chemotherapy followed by surgery (enucleation). External-beam radiation therapy and more chemotherapy may be given after surgery.
Sources: surgery · chemotherapy
Treatment for extraocular retinoblastoma (cancer has spread to the brain) may include the following:
Sources: brain
Systemic or intrathecal chemotherapy and external-beam radiation therapy to the brain and spinal cord.
Sources: intrathecal chemotherapy · spinal cord
Chemotherapy followed by high-dose chemotherapy with stem cell rescue with or without radiation therapy.
Sources: high-dose chemotherapy · stem cell rescue · radiation therapy
It is not clear whether treatment with chemotherapy, radiation therapy, or high-dose chemotherapy with stem cell rescue helps patients with extraocular retinoblastoma live longer.
For trilateral retinoblastoma (retinoblastoma and a brain tumor that occur at the same time), treatment may include the following:
Sources: brain tumor
Systemic chemotherapy followed by surgery and high-dose chemotherapy with stem cell rescue.
Systemic chemotherapy followed by surgery and external-beam radiation therapy.
For retinoblastoma that has spread to other parts of the body, but not the brain, treatment may include the following:
Systemic chemotherapy followed by high-dose chemotherapy with stem cell rescue and external-beam radiation therapy.
Use our clinical trial search to find NCI-supported cancer clinical trials that are accepting patients. You can search for trials based on the type of cancer, the age of the patient, and where the trials are being done. General information about clinical trials is also available.
Sources: clinical trial search · General information
Source: Retinoblastoma Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: October 7, 2021. Captured 2026-09-09.
For information about the treatments listed below, see the Treatment Option Overview section.
Sources: Treatment Option Overview
Treatment of progressive or recurrent intraocular retinoblastoma may include the following:
Sources: progressive · recurrent · intraocular · retinoblastoma
External-beam radiation therapy or plaque radiotherapy.
Sources: External-beam radiation therapy · plaque radiotherapy
Cryotherapy.
Sources: Cryotherapy
Thermotherapy.
Sources: Thermotherapy
Systemic chemotherapy or ophthalmic artery infusion chemotherapy.
Sources: Systemic chemotherapy · ophthalmic · artery · infusion · chemotherapy
Intravitreal chemotherapy.
Sources: Intravitreal chemotherapy
Surgery (enucleation).
Sources: Surgery · enucleation
A clinical trial of targeted therapy with an oncolytic virus that targets the RB1 gene and is injected into the tumor.
Sources: clinical trial · targeted therapy · oncolytic virus · gene · injected · tumor
A clinical trial that checks a sample of the patient's tumor for certain gene changes. The type of targeted therapy that will be given to the patient depends on the type of gene change.
Treatment of progressive or recurrent extraocular retinoblastoma may include the following:
Sources: extraocular
Systemic chemotherapy and external-beam radiation therapy for retinoblastoma that comes back after surgery to remove the eye.
Systemic chemotherapy followed by high-dose chemotherapy with stem cell rescue and external-beam radiation therapy.
Sources: high-dose chemotherapy · stem cell rescue
A clinical trial that checks a sample of the patient's tumor for certain gene changes. The type of targeted therapy that will be given to the patient depends on the type of gene change.
Use our clinical trial search to find NCI-supported cancer clinical trials that are accepting patients. You can search for trials based on the type of cancer, the age of the patient, and where the trials are being done. General information about clinical trials is also available.
Sources: clinical trial search · General information
Intraocular Retinoblastoma
ClinicalTrials.gov recordExtraocular Retinoblastoma
ClinicalTrials.gov recordUnilateral Retinoblastoma
ClinicalTrials.gov recordBilateral Retinoblastoma, Childhood Intraocular Retinoblastoma, Group D Retinoblastoma, Stage I Retinoblastoma, Unilateral Retinoblastoma
ClinicalTrials.gov recordTreatment of Extracranial Metastatic Retinoblastoma
Treatment of Progressive or Recurrent Retinoblastoma
Retinoblastoma